OncoMatch/Clinical Trials/NCT05422690
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Is NCT05422690 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Induction Chemotherapy Triplet Therapy and Consolidation Doublet Therapy: for intrahepatic cholangiocarcinoma.
Treatment: Induction Chemotherapy Triplet Therapy · Consolidation Doublet Therapy: — The purpose of this research is to see if combining gemcitabine, cisplatin and Durvalumab chemotherapy treatments with a direct tumor therapy called Yittrium-90, will work better together to shrink the tumor and control cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: adjuvant therapy with capecitabine
Previous treatment with chemotherapy, intra-arterial or radiotherapy for iCCA is exclusionary, with the exception of adjuvant therapy with capecitabine which is allowed.
Cannot have received: intra-arterial therapy
Previous treatment with chemotherapy, intra-arterial or radiotherapy for iCCA is exclusionary, with the exception of adjuvant therapy with capecitabine which is allowed.
Cannot have received: radiotherapy
Previous treatment with chemotherapy, intra-arterial or radiotherapy for iCCA is exclusionary, with the exception of adjuvant therapy with capecitabine which is allowed.
Lab requirements
Liver function
Noncirrhotic liver required; Child-Pugh score must be less than 5; Child-Pugh B7 or greater cirrhosis excluded; Serum albumin < 3 g/dL excluded; Serum bilirubin > 2 mg/dL excluded; AST or ALT > 5x ULN excluded
Noncirrhotic liver ... Child-Pugh score must be less than 5 ... Serum albumin < 3 g/dL ... Serum bilirubin > 2 mg/dL ... AST or ALT > 5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Keary Janet · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05422690 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, intra-arterial therapy, radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages